Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

SIMPLE SUMMARY: Concurrent platinbased chemoradiotherapy followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the new standard of care for inoperable stage III NSCLC. The present study compares the oncological outcome of patients treated with chemoradiotherapy to those treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Taugner, Julian, Käsmann, Lukas, Eze, Chukwuka, Tufman, Amanda, Reinmuth, Niels, Duell, Thomas, Belka, Claus, Manapov, Farkhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037429/
https://www.ncbi.nlm.nih.gov/pubmed/33807324
http://dx.doi.org/10.3390/cancers13071613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037429/
https://www.ncbi.nlm.nih.gov/pubmed/33807324
http://dx.doi.org/10.3390/cancers13071613

Ejemplares similares